[{"id":"3754f744-f42e-4138-a553-0d22726a464b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05627960","created_at":"2022-11-28T17:58:14.764Z","updated_at":"2024-07-02T16:35:59.944Z","phase":"Phase 1a","brief_title":"First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies","source_id_and_acronym":"NCT05627960","lead_sponsor":"A\u0026G Pharmaceutical Inc.","biomarkers":" PD-L1 • ER • PIK3CA • PGR • BRCA1 • CD4","pipe":" | ","alterations":" PD-L1 expression • PIK3CA mutation • PGR positive","tags":["PD-L1 • ER • PIK3CA • PGR • BRCA1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • PIK3CA mutation • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AG01"],"overall_status":"Recruiting","enrollment":" Enrollment 77","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2022-11-28"}]